Diet & Nutrition for Mental Health | Dr. Chris Palmer

Episode Summary

Executive Summary: Andrew Huberman and Dr. Chris Palmer discuss how metabolic health, especially mitochondrial function, may underlie many psychiatric and neurologic disorders. Palmer shares his own recovery via low-carb eating and describes case studies where ketogenic or carb-restricted diets improved depression, bipolar disorder, schizophrenia, epilepsy, and alcohol use disorder, while emphasizing careful medical supervision and that diet complements—not replaces—medication.

Main Topics: Personal origin story and metabolic syndrome reversal (Priority: 5/5): Palmer explains how his own OCD/depression and later metabolic syndrome led him to try Atkins-style carb restriction, which normalized blood pressure, lipids, prediabetes, and improved mood, energy, sleep, and concentration. Ketogenic diet as a psychiatric intervention (Priority: 5/5): The conversation centers on clinical cases where ketosis or carb restriction produced major improvements in treatment-resistant depression, schizoaffective disorder, bipolar disorder, and schizophrenia, sometimes including remission of hallucinations and paranoia. Epilepsy as the historical foundation (Priority: 5/5): Palmer argues the ketogenic diet gained credibility because it was originally developed for epilepsy, where fasting and ketogenic diets have long been shown to reduce seizures and remain evidence-based for treatment-resistant cases. Mitochondria, metabolism, and mental illness (Priority: 5/5): Palmer presents mitochondria as central regulators of neurotransmitters, hormones, inflammation, epigenetics, and stress responses, proposing mitochondrial dysfunction as a unifying mechanism linking metabolic and psychiatric disease. Diet, fasting, and ketones as tools (Priority: 4/5): The discussion distinguishes between full ketogenic diets, low-carb diets, intermittent fasting, and exogenous ketones, with Palmer noting that different patients may need different levels of carbohydrate restriction and support. Obesity, alcohol, THC, and broader metabolic disease (Priority: 4/5): Palmer extends the framework to obesity and substance use, suggesting obesity may often reflect brain/metabolic dysfunction and citing evidence that ketogenic diets can reduce alcohol withdrawal symptoms and cravings, while THC and alcohol can impair mitochondrial function. Clinical caution, adherence, and individualized care (Priority: 5/5): Both speakers stress that serious psychiatric illness requires supervision, medication changes must be gradual, and adherence is often improved by frequent follow-up, objective ketone monitoring, and tailoring the diet to the patient.

Key Arguments: Palmer’s own metabolic syndrome and mood symptoms improved dramatically after adopting a low-carb/Atkins-style diet, suggesting nutrition can affect both body and mind. Ketosis appears to be a key therapeutic state for some patients; Palmer observed that patients often improved only once urinary or blood ketones were present. The ketogenic diet is not a weight-loss fad in origin; it was developed a century ago to treat epilepsy after fasting was observed to reduce seizures. Mitochondria likely sit at the center of the mechanism because they regulate energy production, neurotransmitter release, inflammation, hormone synthesis, and gene expression. Psychiatric disorders may share metabolic abnormalities, including impaired glucose metabolism and insulin signaling in the brain. For some patients, simply removing ultra-processed/high-sugar foods may help; others, especially with severe illness, may need a true ketogenic diet. Diet should be viewed as one tool among many, not a replacement for medication; medication tapering must be supervised. Adherence is easier when patients experience immediate negative consequences from breaking the diet, such as return of hallucinations or mood symptoms. Exogenous ketones may help some metabolic conditions, but Palmer doubts they can fully substitute for a ketogenic diet in serious psychiatric illness. Obesity may be better understood as a symptom of underlying metabolic/brain dysfunction rather than simply a willpower or calorie-balance problem. Alcohol use disorder may involve brain energy deficits; ketogenic diets reduced withdrawal symptoms and cravings in a pilot trial. THC and alcohol can impair mitochondrial function and may worsen brain health, especially with chronic use.

Data Points: Age at metabolic syndrome diagnosis: 20s - Palmer was diagnosed with high blood pressure, poor lipids, and prediabetes during residency. Diet response time for Palmer: 3 months - His metabolic syndrome resolved after about three months on a low-carb diet. Weight loss: ~10 pounds - Palmer reported losing abdominal fat and about 10 pounds after changing diet. Ketone target for depression: >0.8 mmol - Palmer said he generally aims for blood ketones above 0.8 mmol/L for depression. Ketone target for psychotic disorders/bipolar: >1.5 mmol - He said he usually wants higher ketone levels for psychotic disorders and bipolar disorder. Schizoaffective patient weight loss: 160 pounds - A patient with schizoaffective disorder lost 160 pounds and maintained it. Antipsychotic trials before keto case: 17 medications - The schizoaffective patient had tried 17 different medications before the ketogenic diet. Epilepsy diet efficacy (early reports): 50% seizure-free; 35% with ≥50% reduction - Palmer cited historical ketogenic diet outcomes for epilepsy. Treatment-resistant epilepsy prevalence: ~30% - He noted about one-third of epilepsy patients remain treatment-resistant. French pilot study sample: 31 patients - Pilot study of treatment-resistant mental disorders in a French hospital. French pilot study completion: 28 of 31 - Most participants were able to do and stay on the ketogenic diet. French pilot study improvement: 100% improved; 46% remission - Among those who adhered, all improved and nearly half reached remission. French pilot study medication reduction: 64% - Many were discharged on less medication than at admission. Alcohol trial design: 2 groups - NIH pilot randomized trial compared ketogenic diet vs standard American diet during detox. Alcohol trial outcome: Fewer benzodiazepines, fewer withdrawal symptoms, fewer cravings - Ketogenic diet improved detox outcomes in alcohol use disorder. Alcohol/ketone animal finding: 5-fold higher blood alcohol - Rats on ketogenic diet had much higher blood alcohol levels after the same alcohol dose. Alzheimer’s pilot trial size: 26 subjects - Small crossover trial of low-fat vs ketogenic diet in Alzheimer’s disease. Alzheimer’s trial duration: 12 weeks per diet - Participants crossed over between low-fat and ketogenic diets. Alzheimer’s trial outcome: Improved activities of daily living and quality of life - Benefits were statistically significant when participants were in ketosis. Ketogenic diet adherence challenge: 1,300+ screened; 27 enrolled; 14 completed - Johns Hopkins Alzheimer’s study illustrated difficulty recruiting and retaining participants. Sleep deprivation case: 2-4 hours/night for 6 months - A mental health professional became hypomanic on keto and slept very little. Water fast case: 7 days - A patient with type 2 diabetes and depression fasted for up to seven days under supervision.

Pivotal Quotes: "I believe that mitochondria are the key to the obesity epidemic." — Dr. Chris Palmer: Palmer’s central hypothesis linking obesity, metabolism, and brain health. "The ketogenic diet was developed 100 years ago, 1921, by a physician for one and only one purpose, to treat epilepsy." — Dr. Chris Palmer: Historical explanation for why ketogenic diets have medical legitimacy beyond weight loss. "When they go off the diet, they start hallucinating within 24, 48 hours and they quickly realize that was a really stupid thing to do." — Dr. Chris Palmer: Describing why some severe psychiatric patients adhere strongly to the diet.

Implications: The episode reframes diet as a serious clinical tool for brain health, not just weight loss. It suggests future psychiatry may integrate metabolic assessment, ketone monitoring, and individualized nutrition alongside medication and therapy.